A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis
Launched by AIN SHAMS UNIVERSITY · Jul 24, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different blood tests to see which one better predicts how patients with sepsis from lung infections will do. Sepsis is a serious condition where the body has a strong, harmful response to infection, and it can lead to life-threatening organ problems. The two tests being compared look at certain markers in the blood—the ratio of two types of white blood cells (neutrophils and lymphocytes) and the ratio of lactate (a substance that can build up when the body is stressed) to albumin (a protein in the blood). The goal is to find out which test is more accurate in predicting the outcome for patients with severe infections who are in the intensive care unit (ICU).
Adults between 18 and 80 years old who have a confirmed lung infection causing sepsis and are admitted to the ICU may be eligible to join this study. People who are pregnant, have cancer, or certain other health problems affecting blood protein levels won’t be able to participate. If you join, your doctors will monitor these blood markers to help understand your condition better, but the study mainly involves routine blood tests and careful observation. This research could help doctors improve how they predict and treat sepsis in the future, potentially leading to better care for patients with serious infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults with lower respiratory tract infection
- • Confirmed septic patients (under the third international consensus definitions of sepsis and septic shock),
- • Admitted to intensive care unit.
- • Age (18-80) years.
- • Both genders.
- Exclusion Criteria:
- • Age: \< 18 years old, \> 80 years old
- • Patient refusal.
- • Pregnancy.
- • Malignancy.
- • Pathology that could affect serum albumin concentrations prior to ICU admission as Malnutrition
- • Nephrotic syndrome
- • Liver Cirrhosis
- • Intestinal resection surgeries
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported